Reported 8 months ago
Antro Biotech, a subsidiary of Genovate, announced its foray into the regenerative medicine field by signing a partnership agreement with ToVita Biotech to develop exosome aesthetic medicine products. This move aims to target the aging population in Taiwan and expand internationally, focusing initially on Vietnam and Southeast Asia. ToVita Biotech, specializing in stem cell technology, is engaged in developing stem cell treatments for conditions like knee osteoarthritis and chronic kidney disease. The collaboration may extend beyond exosome skincare products to anti-aging and regenerative medicine offerings worldwide.
Source: YAHOO